The agency has given the go-ahead for a Phase I study of the company’s IO-202 antibody (in combination with Merck’s Keytruda) to treat various tumor types.
A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.
Alkermes to work collaboratively with the Fred Hutchinson Cancer Research Center on the clinical development of a drug candidate as a combination treatment alongside Keytruda.
Rexahn Pharmaceuticals will combine its small molecule compound RX-5902 with Merck’s anti-PD-therapy, Keytruda, to evaluate its efficacy in patients with metastatic triple negative breast cancer.